Rein Therapeutics Inc. (RNTX)
2.00
0.06 (3.09%)
At close: Mar 13, 2025, 3:59 PM
2.02
0.75%
After-hours: Mar 13, 2025, 04:00 PM EDT
Company Description
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases.
It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.
The company was founded by Gregory L.
Verdine, Rosana Kapeller, Huw M.
Nash, Joseph A.
Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Rein Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 29, 2017 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Dr. James Brian Windsor Ph.D. |
Contact Details
Address: No Address available Austin, United States | |
| Website | http://www.reintx.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 00887A204 |
| ISIN Number | US00887A2042 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. James Brian Windsor Ph.D. | Chief Executive Officer, President & Director |
| Timothy M. Cunningham CPA, M.B.A. | Interim Chief Financial Officer & Principal Accounting Officer |
| Dr. Cory M. Hogaboam Ph.D. | Chief Scientific Officer |